To ask the Scottish Executive from what date clinicians were advised that they can prescribe the anti-TNF drugs, etanercept and Infliximab, whenever it is clinically appropriate in an individual case.
The Health Technology Board forScotland (HTBS) (now part of NHS Quality Improvement Scotland) issued advice onthe use of etanercept and infliximab on the following dates:
17 May 2002 - Comment on theNational Institute for Clinical Excellence (NICE) Technology Appraisal Guidancenumber 35 on the use of etanercept for the treatment of juvenile idiopathic arthritis.
17 May 2002 - Comment on theNICE Technology Appraisal Guidance number 36 on the use of etanercept and infliximabfor the treatment of rheumatoid arthritis.
28 June 2002 - Comment on the NICE Technology Appraisal Guidance number40 on the use of infliximab for Crohn’s disease.
The comments can be accessedat www.nhshealthquality.org.
On 12 July 2004, the Scottish MedicinesConsortium (SMC) issued advice to NHSScotland about the use of infliximab for thetreatment of ankylosing spondylitis in patients who have severe axial symptoms,elevated serological markers of inflammatory activity and who have responded inadequatelyto conventional therapy. On the same date, the SMC also advised on the use of etanerceptfor the treatment of active and progressive psoriatic arthritis in adults. The SMCadvice can be accessed at www.scottishmedicines.org.
In each case, the HTBS and theSMC advised that NHSScotland should take account of the advice and ensure that recommendeddrugs and treatments are made available to meet clinical need.